{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-006692","form_type":"8-K","ticker":"SDGR","cik":"0001490978","company_name":"Schrodinger, Inc.","filed_at":"2022-02-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.699174+00:00","generated_at":"2026-06-27T04:45:14.912260+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Schrödinger Q4 software revenue $38.6M, up 55% YoY; guides 2022 total revenue $161-181M","bullets":["Q4 total revenue $46.2M (+40% YoY); software revenue $38.6M (+55% YoY); drug discovery $7.6M.","FY 2021 total revenue $137.9M (+28% YoY); net loss $101.2M vs $26.6M loss in 2020.","2022 guidance: total revenue $161-181M; software $126-136M; drug discovery $35-45M; gross margin mid-70s%.","Karen Akinsanya promoted to president of R&D; MALT1 IND H1 2022; Phase 1 study in H2 2022.","Cash $579M; ACV $112.1M (+22% YoY); 190 customers >$100k ACV."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-006692","json":"https://secwatch.observer/filing/0001564590-22-006692.json","markdown":"https://secwatch.observer/filing/0001564590-22-006692.md","text":"https://secwatch.observer/filing/0001564590-22-006692.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1490978/000156459022006692/0001564590-22-006692-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1490978/000156459022006692/sdgr-8k_20220224.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T04:45:14.912260+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}